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Abstract
Using deep phenotyping and high-throughput sequencing, we have identified a novel type of distal myopathy caused by 
mutations in the Small muscle protein X-linked (SMPX) gene. Four different missense mutations were identified in ten 
patients from nine families in five different countries, suggesting that this disease could be prevalent in other populations as 
well. Haplotype analysis of patients with similar ancestry revealed two different founder mutations in Southern Europe and 
France, indicating that the prevalence in these populations may be higher. In our study all patients presented with highly 
similar clinical features: adult-onset, usually distal more than proximal limb muscle weakness, slowly progressing over 
decades with preserved walking. Lower limb muscle imaging showed a characteristic pattern of muscle involvement and 
fatty degeneration. Histopathological and electron microscopic analysis of patient muscle biopsies revealed myopathic find-
ings with rimmed vacuoles and the presence of sarcoplasmic inclusions, some with amyloid-like characteristics. In silico 
predictions and subsequent cell culture studies showed that the missense mutations increase aggregation propensity of the 
SMPX protein. In cell culture studies, overexpressed SMPX localized to stress granules and slowed down their clearance.
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Introduction
Distal myopathies are a clinically, histopathologically and 
genetically heterogeneous group of inherited skeletal mus-
cle diseases. In some entities the muscle weakness remains 
restricted to the distal muscles, and in others involvement of 
the proximal muscles may occur as the disease progresses 
[26]. Over the years, deep phenotyping, including muscle 
imaging and histopathological evidence, and molecular 
genetics have resulted in the identification of more than 25 
genes related to distal myopathies [33]. Advancements in 
high-throughput sequencing (HTS) have increased the rate 
of molecular diagnosis for families with inherited rare neu-
romuscular disorders. However, over 40% of patients, in par-
ticular singletons, still remain without conclusive molecular 
diagnosis often due to lack of sufficient family data and 
material [12, 32]. To consider pathogenicity of previously 
unknown genes as causative for a neuromuscular disease, 
either more than one family with similar phenotype or a very 
large family is needed.
Using deep phenotyping, HTS and subsequent functional 
studies, we describe here a novel adult-onset distal myopathy 
observed in ten patients sharing common clinical features, 
characteristic muscle imaging (MRI) features, histopatho-
logical findings and missense variants in the novel myopathy 
gene SMPX.
SMPX (also known as Chisel, CSL) is a proline-rich pro-
tein of 88 amino acids (9 kDa). It is predominantly expressed 
in skeletal muscles and heart, with a costameric and intermy-
ofibrillar localization and highest expression in slow mus-
cle fibers [29]. When overexpressed in mouse myoblasts, it 
associates with focal adhesion proteins, promotes myoblast 
fusion, and modulates actin turnover and cell shape upstream 
of Rac1 and p38 [29, 35]. While mutations causing total 
 * Mridul Johari 
 mridul.johari@helsinki.fi
Extended author information available on the last page of the article
376 Acta Neuropathologica (2021) 142:375–393
1 3
loss of SMPX have been reported to cause hearing loss, 
its molecular role and function in skeletal muscle remains 
largely unknown.
Our functional studies show that the four different patho-
genic missense mutations in SMPX observed in our patients 
make the mutant SMPX protein aggregation prone. The 
pathological effect is observed as prominent sarcoplasmic 
protein inclusions in the muscle fibers of patients.
Materials and methods
Patients and clinical examinations
All patients underwent clinical neurological examination. 
Besides the 10 affected patients, we collected blood sam-
ples for DNA analysis from 8 asymptomatic family members 
from 9 families (Fig. 1a). All muscle biopsies were obtained 
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Fig. 1  a Pedigrees of the families included in the study. DNA sam-
ples were collected from the individuals marked with an asterisk. 
Corresponding gentoypes are displayed for these individuals where 
 Xm represents a mutated allele and X represents a wild-type allele. 
F7 II.3 is indicated as suffering from poliomyelitis and thus was not 
included in the study. b Haplotype analysis, showing the Haplo-
type A (Italian/Maltese haplotype) observed in Families F1–F2 and 
Haplotype B (French haplotype) observed in F6–F7 along with the 
corresponding age of the haplotypes. c A summary of the identified 
missense mutations in SMPX and their correlation with the observed 
phenotypes in F1–F9
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were approved by institutional review boards. The study was 
performed according to the Declaration of Helsinki.
Ethical approval for this study falls under 
HUS:195/13/03/00/11. Informed consent from the patients 
was obtained at the time of sample collection.
Muscle imaging data, electrophysiological examina-
tion results (nerve conduction studies and needle electro-
myogram, EMG), creatine kinase (CK) measurements and 
cardiac function test results were obtained in most patients 
(Table 1). Muscle MRI findings (Fig. 2) with axial sections 
of the lower limb muscles were evaluated in 8 patients, in 
two of whom (F2 II.2 and F6 II.1) also the shoulder girdle/
upper limb muscles were imaged. Echocardiography was 
performed in 9 patients.
Muscle biopsy and immunohistochemical studies
Snap-frozen muscle samples were obtained from seven 
probands and processed with routine muscle histopatho-
logical procedures, including hematoxylin & eosin, modi-
fied Gomori’s trichrome, NADH tetrazolium reductase, 
and COX-SDH stainings [4]. Immunofluorescent analysis 
using standard methodology was performed using the fol-
lowing primary antibodies: rabbit polyclonal anti-SMPX 
(PA3-070, Thermo Fisher Scientific, RRID:AB_2540497), 
rabbit polyclonal anti-LC3b (2775, Cell Signaling Tech-
nology, RRID:AB_915950) rabbit polyclonal anti-p62 
(P0067, Sigma-Aldrich, RRID:AB_1841064), mouse 
monoclonal anti-TDP-43 (clone 2E2-D3, Sigma-Aldrich, 
RRID:AB_10806030), mouse monoclonal anti-αB-crystallin 
(ABCrys-512, Leica Biosystems, RRID:AB_442024), 
mouse monoclonal anti-vinculin (ab130007, Abcam, 
RRID:AB_11156698), rabbit polyclonal anti-BAG3 (10599-
1-AP, Proteintech, RRID:AB_2062602), rabbit polyclonal 
anti-HSPB8 (ab79784, Abcam, RRID:AB_1603573), rab-
bit monoclonal anti-TIAL1 D32D3 (8509, Cell Signaling 
Technology, RRID:AB_10839263) and goat polyclonal 
anti-eIF3η (N-20, sc-16377, Santa Cruz Biotechnology, 
RRID:AB_671941). Alexa Fluor 488/546 -conjugated sec-
ondary antibodies (Thermo Fisher Scientific) were used for 
detection, and nuclei were counterstained with Hoechst. 
In addition, DAB immunostaining was performed using 
mouse monoclonal anti-myotilin (NCL-MYOTILIN, Leica 
Biosystems, RRID:AB_563903), mouse monoclonal anti-
desmin (MU 072-UC, BioGenex), mouse monoclonal anti-
phosphorylated neurofilament H (clone SMI-31, BioLegend, 
RRID:AB_2564641), and rabbit polyclonal anti-ubiquitin 
(Z458, Agilent/Dako, RRID:AB_2315524). Menadione and 
alkaline Congo red [9] stainings were performed on patient 
F9 II.1. Staining with Amytracker 680 (Ebba Biotech AB, 
Solna, Sweden) was performed on patient F8 III.1. Micro-
scopic images were obtained using the Zeiss Axio Imager 
M2 system (Carl Zeiss AG) or a Leica TCS SP8 confocal 
microscope (Leica Microsystems). Ultrathin sections were 
prepared for electron microscopy and examined with a JEOL 
1400 transmission electron microscope (JEOL, Japan). Elec-
tron micrographs were obtained using the Olympus-SIS 
Morada digital camera (Olympus Soft Imaging Solutions, 
Münster, Germany).
Molecular genetic analyses
Genomic DNA from probands and available and informa-
tive family members (Fig. 1a) was isolated from blood cells 
using standard techniques.
The proband F1 II.1 underwent Exome Sequencing (ES) 
using SeqCap EZ Human Exome Library v2.0 (Roche, USA) 
at FIMM (Helsinki, Finland). Raw reads were aligned using 
BWA on UCSC hg19 reference genome and variants were 
called according to GATK recommendations. Variant anno-
tation was done using Annovar. ES results were first filtered 
on standard quality parameters and then using a minor 
allele frequency of 0.001 in ExAC and gnomAD databases. 
Thereafter, we focused on unique variants in a list of muscle-
expressed genes from the skeletal muscle transcriptome [21, 
38, 40]. Upon identification of a novel variant, SMPX was 
included as a candidate gene in the revised MYOcap [5] and 
Motorplex [31] gene panels. Probands of F2–F9 underwent 
sequencing using MYOcap/Motorplex targeted gene panels.
SMPX variants are annotated following the reference 
sequences: NM_014332.3 (transcript) and NP_055147.1 
(protein). PrimateAI [37], CADD, MutationTaster, SIFT 
and PolyPhen2 were used to assess the in silico pathogenic-
ity of the variants, and SpliceAI [14] was used to predict 
their potential effects on splicing. Variant pathogenicity 
was evaluated according to the ACMG-AMP guidelines and 
revised suggestions made in case of lack of available fam-
ily members for cosegregation [15]. Validation and Sanger 
sequencing of SMPX variants was done by PCR. SNP geno-
typing was performed on Illumina Infinium Global Screen-
ing Array + MD v 2 (GSAMD-24v2), with 759,993 markers 
using DNA samples from family members in F1, F2 and F3, 
F4 for haplotype analysis.
Plasmid constructs
Wild-type human SMPX ORF was cloned to pCDNA3.1/
V5-His-TOPO (Thermo Fisher), to produce a C-terminally 
V5/His6-tagged SMPX construct (SMPX-V5). Missense 
mutations were introduced to the construct by site-directed 
mutagenesis. Wild-type and mutant SMPX were then cloned 
in frame with an N-terminal Myc tag to pSBtet-Hyg [18] 
(a gift from Eric Kowarz; Addgene plasmid # 60,508; 
RRID:Addgene_60508) to produce pSBtet-Hyg-Myc-SMPX 
constructs.
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Fig. 2  Magnetic resonance imaging (MRI) T1 sequences of patients 
with SMPX distal myopathy. a Patient F1 II.1 at 57 yrs showing nor-
mal thighs but fatty degeneration in lower legs: anterior compart-
ment and medial gastrocnemius muscles. b F2 II.2 at 61 yrs show-
ing minor degenerative change in thigh muscles semimembranosus, 
biceps femoris and left vastus intermedius; fatty degenerative changes 
in the anterior compartment muscles more on the left of proximal 
lower leg and fatty replacement of anterior compartment and part of 
the soleus muscles in the distal lower legs. c F3 II.1 at 58 yrs (left 
lower limb) with normal thigh and severe fatty degeneration in lower 
leg anterior compartment, medial gastrocnemius and medial part 
of distal soleus. d F6 II.1 at 52 yrs showing normal thigh and fatty 
degenerative changes in the anterior compartment (more on the right) 
and medial gastrocnemius muscles of proximal lower leg, and ante-
rior compartment with soleus muscles in the distal lower legs. e F6 
II.1 at 60 yrs with early degenerative changes in biceps femoris and 
semimembranosus in the thigh and more fatty degeneration of ante-
rolateral compartments and of medial gastrocnemius and soleus in the 
lower legs. f F7 II.1 at 56 yrs shows milder fatty degeneration in vas-
tus intermedius and medialis, semimembranosus and biceps femoris 
on the thigh, and in both posterior and anterior compartments on the 
lower legs, less in the lateral peroneal muscles. g F8 III.1 at 58 yrs 
shows lower legs with severe fatty replacement of anterior compart-
ments and medial heads of gastrocnemius and milder changes in the 
soleus. h F9 II.1 at 76 yrs showing pronounced fatty degeneration in 
thighs: more in hamstrings than the lateral and intermediate vastus of 
the quadriceps, severe changes in distal lower leg anterior compart-
ment and soleus muscles and peroneals more on the right
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Aggregation prediction
The effect of the variants on amyloid aggregation of SMPX 
was predicted using the PASTA 2.0 server (http:// old. prote 
in. bio. unipd. it/ pasta2/) [39].
Analysis of SMPX solubility
To evaluate the solubility of the SMPX protein, wild-type 
and mutant SMPX-V5 constructs were expressed in HeLa 
cells for 3 d. The cells were pelleted in PBS, lysed in RIPA 
buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% Triton 
X-100, 0.5% sodium deoxycholate, 0.1% SDS) supplemented 
with 1 mM  MgCl2, 1× HALT Protease Inhibitor Cocktail 
(Thermo Fisher) and 25 U/ml of Pierce Universal Nucle-
ase for Cell Lysis (Thermo Fisher) by rotating 60 min at 
8 °C, and triturated through a 27G needle. Supernatant and 
pellet fractions were separated by centrifugation (16,000g, 
15 min at 4 °C). The pellets were washed once with RIPA 
buffer and centrifuged as above. The samples were com-
bined with 2× SDS sample buffer with 10% 2-mercaptoe-
thanol and heated 5 min at 95 °C and analyzed by west-
ern blotting using antibodies against the V5 tag (Thermo 
Fisher R960-25, RRID:AB_2556564), tubulin (YL1/2, 
Abcam ab6160, RRID:AB_305328), and histone 3 (Abcam 
ab1791, RRID:AB_302613). Total protein was stained with 
the Revert 700 Total Protein Stain (LI-COR, Lincoln, NE, 
USA) and detected with an Odyssey scanner.
Microscopic analyses of HeLa cells
For microscopic analyses, HeLa cells were plated on cov-
erslips in 24-well plates and transfected with SMPX-V5 
constructs (500 ng/well) using FuGENE 6. Three days after 
transfection, the cells were treated with 20 µM MG132 
(Sigma-Aldrich) for 2 h or left untreated. Cells were washed 
with PBS and fixed with 4% PFA for 15 min. Immunofluo-
rescence stainings were performed with the following anti-
bodies: V5 mouse mAb (RRID:AB_2556564), V5 rabbit 
pAb (Sigma-Aldrich AB3792, RRID:AB_91591), TIA1 goat 
pAb (Abcam ab61700, RRID:AB_945832), TIAL1 rabbit 
pAb (Abcam ab26257, RRID:AB_470826), TIAL1 rabbit 
mAb D32D3 (RRID:AB_10839263), G3BP mouse mAb 
(Abcam ab56574, RRID:AB_941699), HNRNPA1 mouse 
mAb 9H10 (Abcam ab5832, RRID:AB_305145), eIF3η goat 
pAb (RRID:AB_671941), and Oligomer A11 rabbit pAb 
(Thermo Fisher AHB0052, RRID:AB_2536236). Nascent 
proteins were labeled and detected with the Click-iT Plus 
OPP Alexa Fluor 594 Protein Synthesis Assay Kit (Thermo 
Fisher) according to the manufacturer’s instructions. Images 
were acquired with Zeiss Axio Imager M2 using 40× NA 
1.30 and 20× NA 0.80 objectives, or with a Leica TCS SP8 
confocal microscope using a 40× NA 1.10 objective (Leica 
Microsystems).
Quantitative SG analyses
For SG quantitation experiments, HeLa cells were cul-
tured on coverslips or 96-well plates (ViewPlate-96, Perki-
nElmer) and transfected with SMPX-V5 constructs. Three 
days after transfection, the cells were left non-treated, fixed 
immediately after stress treatment (20 µM MG132 2 h or 
500 µM sodium arsenite 45 min), or washed once with 
warm culture medium and recovered in fresh medium for 
1 or 3 h after stress. Cells were fluorescently stained with 
V5 and TIAL1 antibodies and Hoechst, and imaged with a 
20× NA 0.80 objective on Zeiss Axio Imager M2 (MG132 
experiments; coverslips) or a 20× NA 0.40 objective on 
the ImageXpress Pico instrument (arsenite experiments; 
96-well plates). Automated image analysis was performed 
using the CellProfiler 4.0.5 software [25]. Briefly, SMPX-
transfected and untransfected cells were identified based on 
V5 staining intensity, and cytoplasmic TIAL1 spots were 
identified as SGs. In V5-positive cells, median V5 signal 
intensity of the SGs and the surrounding donut of 5 pixels 
was determined, and those with the intensity ratio > 1.2 were 
classified as V5-enriched. Data were collected from four 
independent experiments, and group means (proportion of 
SG-containing cells and mean number of SGs per analyzed 
cell) from the replicate experiments were compared using 
two-way repeated-measures ANOVA or repeated-measures 
mixed model test with the Geisser–Greenhouse correction 
and Dunnett’s multiple correction test.
C2C12 cell experiments
C2C12 myoblasts were cultured in growth medium (pyru-
vate-free DMEM with 20% FCS, Glutamax, and penicillin/
streptomycin). For differentiation into myotubes, myoblasts 
were grown to confluency on collagen-coated dishes and 
then cultured 3 d in differentiation medium (pyruvate-free 
DMEM with 2% heat-inactivated horse serum, L-glutamine, 
and penicillin/streptomycin) supplemented with 10% OPTI-
MEM I (Thermo Fisher Scientific), and additional 1–2 d in 
differentiation medium alone.
In transient transfection experiments, subconfluent 
C2C12 myoblasts were transfected with SMPX-V5 con-
structs using Lipofectamine 3000 (Thermo Fisher Scien-
tific), and differentiation was started on the following day.
To create C2C12 cells with inducible expression of Myc-
SMPX, C2C12 myoblasts were cotransfected with wild-
type or mutant pSBtet-Hyg-Myc-SMPX and pCMV(CAT)
T7- SB100 [24] (a gift from Zsuzsanna Izsvak; Addgene 
plasmid # 34879, RRID:Addgene_34879) in a 9:1 ratio 
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using Lipofectamine 3000. Polyclonal pools of stably trans-
fected cells were selected in growth medium with 200 µg/ml 
hygromycin B (Thermo Fisher Scientific) and maintained in 
growth medium with 50 µg/ml hygromycin B. Myc-SMPX 
expression in myoblasts or differentiating myotubes was 
induced with 10 µg/ml doxycycline 2 days before fixing. 
Heat shock (45 °C 1 h) was used to induce SG formation 
in myoblasts.
IF stainings were performed with V5 mouse mAb 
(RRID:AB_2556564), TIAL1 rabbit mAb D32D3 
(RRID:AB_10839263), and Myc-tag (9B11) mouse mAb 
(2276, Cell Signaling Technology, RRID: AB_331783).
Results
Clinical findings
In all ten families, except the two brothers in F5, all probands 
reported negative family history of muscle weakness and 
presented as sporadic cases (Fig. 1a). In the probands of 
families F1–F5, onset of finger extensor/ankle dorsiflexor 
weakness was observed in the 3rd–4th decade. Thereafter, 
the symptoms slowly progressed over decades to severe 
distal more than proximal upper and lower limb weakness 
(Table 1). The observed clinical phenotype was consistent 
with some individual variations as seen in the probands of 
F6–F9, and remarkably with retained walking capacity even 
in the oldest patient in F9 at the age of 80 years. Cardiac 
evaluations with echocardiography were normal and no 
hearing loss was recorded even at higher age (Table 1). Mus-
cle imaging of the patients showed a characteristic MRI pat-
tern of muscle involvement (Fig. 2) with fatty replacement in 
the anterior compartment muscles of the lower legs, later in 
the calf muscles medial gastrocnemius and soleus, and very 
late changes in the thigh muscles more in the hamstrings.
Molecular genetics
We analyzed the HTS data from the probands for potential 
disease-causing variants that could explain their disease 
phenotype but did not identify causative variants in any of 
the known neuromuscular disease genes. Prioritizing unique 
variants in genes expressed in skeletal muscles [21, 38, 40] 
but not known to cause muscle disease, we observed the 
same variant c.233G > A (p.S78N) in the SMPX gene first 
in F1 and later in all probands of F2–F5. The variant was 
not present in any of the available healthy family members 
(Fig. 1a). Three additional SMPX variants (Fig. 1c) were 
identified after including SMPX as a candidate in our gene 
panels [5, 31] in the probands of four additional families: 
c.79C>G (p.P27A) in families F6 and F7 with French 
ancestry, c.38C>T (p.A13V) in the German family F8, and 
c.19C>A (p.P7T) in the Finnish family F9. None of the iden-
tified mutations were predicted to affect splicing by SpliceAI 
[14].
The observed mutations were absent in public genome 
aggregation databases except for the very late onset 
c.19C>A (p.P7T), which has a population frequency of 
2.92 ×  10–5 (6/205,256 alleles) in the Genome Aggregation 
Database (gnomAD). Families F1–F5 shared ancestral his-
tory tracing back to Malta. SNP genotyping of F1 and F2 
revealed a common haplotype of chrX:17499443–22849591 
amounting to 5.35 Mb (Fig. 1b). The shared haplotype 
spanned a mean length of 8.07 cM and was estimated to be 
approximately 25 generations or 625 years old [8, 30]. The 
French families F6–F7 shared in chrX:12750254–32544555 
a haplotype of 19.79 Mb (25.5 cM), going back to approxi-
mately eight generations or 200 years (Fig. 1b).
Histopathology, immunohistochemistry 
and electron microscopy (EM)
Histopathological analysis of muscle biopsies from our 
patients (Table 1) showed general myopathic changes of 
variable severity, including fiber size variation, internal 
nuclei, rimmed vacuolar pathology and sarcoplasmic inclu-
sions, which stained positive with antibodies against SMPX, 
SQSTM1/p62, SMI-31, ubiquitin, and the known SMPX-
interacting protein vinculin (Figs. 3, 4). The protein inclu-
sions showed sarcoplasmic and subsarcolemmal localiza-
tion. Neither SMPX-positive protein inclusions, nor other 
SMPX accumulation was observed in any other disease con-
trol myopathies with rimmed vacuolar and/or myofibrillar 
pathology (2 × HMERF, 2 × sIBM, 1 × LGMD1D, 1 × WDM, 
and 1 × MFM with unknown etiology, data not shown). We 
observed more sarcoplasmic inclusions and SMPX accumu-
lation pathology in the older patients with the N-terminal 
SMPX mutations (p.P7T, p.A13V and p.P27A) compared 
to the patients with the p.S78N mutation, located close to 
the SMPX C-terminus. Menadione staining in patient F9 II.1 
remained negative (not shown).
The inclusions and protein accumulations were hetero-
geneous. In Herovici staining, two kinds of protein aggre-
gates were seen: orange-red stained bodies and other protein 
aggregates showing dark staining (not shown). Gomori’s 
trichrome showed pale blue protein inclusions, dark blue 
granular staining, and some protein inclusions with red 
staining (Fig. 3d). In addition, we observed less prominent 
myofibrillar pathology immunoreactive for myotilin and 
αB-crystallin. The myofibrillar lesions showed reactivity for 
the CASA complex constituents BAG3 and HSPB8, both 
of which also accumulated in a proportion of fibers con-
taining SMPX inclusions (Fig. 4k, l). There was no marked 
desmin accumulation, and TDP-43 did not show any positive 
immunolabeling (Fig. 3h, l). Summary of the most relevant 
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Fig. 3  Histochemical and DAB immunohistochemical stainings. a 
Hematoxylin & eosin (HE) staining shows fiber size variation and 
internal nuclei, multiple cytoplasmic inclusions are present showing 
sarcoplasmic and subsarcolemmal localization (arrows). b, c Rimmed 
vacuoles (arrows) are observed in HE (b) and immunostaining for 
the autophagosome marker LC3b (c). d In Gomori’s trichrome, sar-
coplasmic inclusions show red labeling. e, f Enzyme histochemical 
COX-SDH e and mitochondrial NADH diaforase f stainings show 
small irregular sarcoplasmic areas of reduced activity. g Myofibril-
lar protein accumulation as shown by myotilin staining is present in 
several fibers in DAB immunostaining, whereas desmin h does not 
accumulate in a similar manner. i–l In p62/SQSTM1, ubiquitin and 
SMI-31 stainings, multiple positive protein inclusions and punctate 
labeling are observed in nearly all fibers, whereas TDP-43 staining 
remains negative. Panels f–l are serial sections. Scale bars = 100 µm
385Acta Neuropathologica (2021) 142:375–393 
1 3
immunohistochemical findings in sarcoplasmic inclusions 
vs. myofibrillar lesions is presented in Supplementary 
Table 1 (online resource). The sarcoplasmic inclusions in 
patient F9 II.1 muscle showed Congo red fluorescence when 
viewed with fluorescent microscope using Texas red filter, 
suggesting amyloid-like aggregation (Fig. 5a). In polarized 
light microscopy, the protein inclusions showed apple-green 
birefringence (not shown). Similarly, sarcoplasmic inclu-
sions in patient F8 III.1 stained positive with the amyloid 
dye Amytracker 680 (Fig. 5b).
EM of patient muscles did not reveal major disorganiza-
tion of sarcomeric structures; M-bands were intact whereas 
the alignment of Z-discs was irregular (not shown). In EM 
analysis of F9 II.1, some sarcoplasmic inclusions were dis-
tinct with sizes in the range of 1–5 µm, consisting of non-
branching filamentous aggregates/inclusions, and partly 
surrounded by autophagic myeloid structures (Fig. 5c–e). 
Some inclusions were compatible with cytoplasmic bodies, 
and sarcolemmal structures appeared intact.
SMPX solubility analyses
In silico sequence analysis with Pasta2.0 [39] identified a 
region with high probability for parallel amyloid aggregation 
in the N-terminal part of wild-type SMPX, and this was fur-
ther increased by the two N-terminal mutations (p.P7T and 
p.A13V) (Fig. 6a). Fractionation experiments of transfected 
HeLa cells were in excellent agreement with the prediction; 
they supported clearly reduced solubility of SMPX p.P7T 
and p.A13V, whereas the C-terminal mutations showed a 
minor yet significant effect (Fig. 6b, c).
Cell culture studies and SG dynamics
To study if mutations affect the subcellular localization 
of SMPX, we performed IF microscopy on cultured cells. 
Both SMPX-V5 expressed in HeLa cells and Myc-SMPX 
expressed in C2C12 myoblasts showed cytoplasmic and 
nuclear localization, with patterns ranging from mostly dif-
fuse to filamentous/granular/fibrillar, but no obvious differ-
ences between wild-type and mutant constructs (Supple-
mentary Fig. 1, online resource). Some cells showed SMPX 
enrichment at cell edges or focal adhesions consistent with 
previous studies [29, 35]. We also aimed at studying SMPX 
localization in C2C12 myotubes, but both transient and 
stable transfection strategies produced few well-developed 
myotubes with sufficient SMPX expression levels. The small 
number of analyzed myotubes did not reveal localization 
differences between wild-type and mutant constructs (Sup-
plementary Fig.1, online resource).
Remarkably, some transfected HeLa cells showed locali-
zation of SMPX-V5 to stress granules (SG), ribonucleopro-
tein foci that form upon cellular stress by liquid–liquid phase 
separation [2]. These stained variably positive for several SG 
components (TIA1, TIAL1, G3BP, eIF3 and HNRNPA1) as 
well as the amyloid oligomer antibody A11, and suppressed 
protein synthesis further suggested that they are bona fide 
SGs (Fig. 7a, Supplementary Fig. 2). However, even under 
stress conditions, most of SMPX-V5 was not localized in 
SGs, and not all SGs in transfected cells contained visible 
SMPX-V5. Similarly, in C2C12 myoblasts subjected to heat 
shock, Myc-SMPX showed infrequent localization to SGs 
(Supplementary Fig. 2, online resource).
Diseases such as multisystem proteinopathy (MSP), 
amyotrophic lateral sclerosis, frontotemporal dementia and 
myopathies are associated with impaired SG dynamics or 
clearance [11, 16, 19, 20, 23]. To study how SMPX affects 
SG dynamics in transfected HeLa cells, we performed auto-
mated image analysis of TIAL1-positive SGs in non-stressed 
cells, immediately after stress treatments (proteasome inhibi-
tion with MG132 or oxidative stress with sodium arsenite), 
and after recovery. To these studies, we included p.A13V 
and p.S78N as examples of mutations with higher and lower 
effects on SMPX solubility. Compared to SMPX-negative 
cells, SMPX-expressing cells showed a higher proportion 
of SG-containing cells and increased number of SGs per 
cell, both in baseline and during recovery, indicating that 
SMPX can affect SG dynamics (Fig. 7b–c, Supplementary 
Fig. 2, Supplementary Tables 2, 3). Wild-type and mutant 
SMPX constructs did not show a dramatic difference in this 
experimental setup, although a significant difference in SG 
number per cell was seen between wild-type and p.S78N in 
1-h recovery after MG132 stress, and a similar trend was 
apparent in arsenite experiments. Moreover, SGs enriched 
for SMPX-V5 showed delayed recovery after MG132 stress 
(Fig. 6d, Supplementary Table 4).
Discussion
Our results demonstrate that missense mutations in SMPX 
cause a previously unidentified muscle disease, a distal 
myopathy with some amyloidogenic characteristics of the 
mutant protein. Patients have a characteristic clinical phe-
notype of adult-onset progressive loss of muscle tissue, first 
in the forearm and lower legs with later involvement of other 
skeletal muscles but sparing the heart muscle.
SMPX is also expressed in the hair cells of the inner ear 
[13, 34, 36], and variants causing a loss-of-function cause 
hereditary progressive non-syndromic hearing loss (NSHL, 
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Fig. 4  Immunofluorescence microscopy. a–f Immunofluorescent 
double staining; merged images are shown, SMPX is green and 
CRYAB is magenta. In control skeletal muscle (ctrl) free of neu-
romuscular disease, SMPX shows diffuse cytoplasmic and focal 
subsarcolemmal staining pattern. Muscle biopsy of F1 II.1 b shows 
moderate SMPX accumulation in a single fiber (white arrowhead), 
whereas in patient F2 II.2 c there is no SMPX accumulation. In 
probands from families F7, F8 and F9 (d–f), multiple SMPX-pos-
itive sarcoplasmic inclusions are present in several fibers. In F8 
III.2 (e) and F9 II.1 (f), separate myofibrillar CRYAB accumula-
tion is observed (white arrowheads), which does not co-localize 
with SMPX labeling. g–i Double immunostaining of F6 II.1. Sin-
gle channel and merged images are shown; SMPX is green, vinculin 
is magenta. SMPX-positive protein inclusions (g) are also positive 
for vinculin (h), merged image (i). j–l; serial sections Myofibrillar 
accumulation (arrow) is positive for myotilin (j), and also for the 
CASA proteins BAG3 (k) and HSPB8 (l). m–n; serial sections) 
Several (atrophic) fibers show sarcoplasmic up-regulation of both 
BAG3 (m) and (n) HSPB8. Scale bars = 100 µm
◂
OMIM 300066) [1, 3, 7, 13, 22, 27, 28, 36] without reported 
skeletal myopathy. In our families, in contrast, affected adult 
males examined in their 6th–8th decades showed no hearing 
loss and neither reported any hearing impairment in their 
relatives. Interestingly, the first SMPX missense mutation 
causing hearing loss was recently described [10]. Replacing 
the C-terminal glutamine residue of SMPX with glutamate, 
this mutation creates a C-degron motif EE that is predicted 
to destabilize the protein [17], likely resulting in a hypomor-
phic allele pathomechanistically similar to the other hearing-
loss mutations.
Our findings suggest that the missense variants described 
here cause muscle disease through a gain-of-function 
mechanism of mutant SMPX, contrasting with the loss-of-
function mutations associated with hearing loss. The patho-
mechanism appears to be based mainly on aggregation of the 
mutant protein. The predicted and experimentally confirmed 
effect of the mutations on protein solubility correlates with 
the accumulation of SMPX in sarcoplasmic inclusions in 
patient muscle fibers, which is specific for this disease. In 
addition, resemblance to other myofibrillar myopathies was 
observed as myotilin-positive myofibrillar lesions also con-
tain BAG3 and HSPB8. One possibility is that the myofibril-
lar pathology could reflect prolonged overload of the chaper-
onal proteostasis machinery, including the Z-disc associated 
chaperone-assisted selective autophagy (CASA) complex, 
due to SMPX aggregation.
The observed association of SMPX with SGs may also be 
of interest for the pathomechanism. Normal SGs are highly 
dynamic and dissolve quickly when the stress is over. How-
ever, prolonged stress, mutations in SG components, and 
accumulation of defective ribosomal products into SGs can 
interfere with dynamic behavior of SGs, rendering them into 
insoluble aggregates that need to be actively disassembled 
by chaperones or removed by autophagy [6]. In this con-
text it is of particular interest that the clinical picture of our 
patients resembles that caused by TIA1 mutations [11, 20]. 
Welander distal myopathy results from a missense change 
in the prion-like domain of TIA1 [11], whereas a variant 
affecting a nearby amino acid residue leads to an identical 
distal myopathy phenotype in combination with SQSTM1 
mutations [20]. Both of these mutations alter the prion-like 
behavior of TIA1, increasing its propensity to form SGs [11, 
20]. Our results suggest that SMPX has the potential to inter-
fere with the normal dissolution of SGs, and accordingly, 
the difficulty to express high levels of SMPX in both HeLa 
and C2C12 cell culture systems may be due to translational 
repression. The variable abnormal changes of SG proteins in 
patient muscle are also compatible with possible SG involve-
ment (Supplementary Fig. 2, online resource). However, as 
our experiments did not reveal major differential effects on 
SG dynamics between wild-type and mutant SMPX, the 
potential role of SGs in the pathomechanism remains unclear 
and should be addressed in further studies in experimental 
systems allowing longer-term SMPX expression.
The identification of one common founder haplotype in 
the Italian/Maltese families and another in the French fami-
lies suggest that missense variants in SMPX may be a more 
frequent cause of distal myopathy in these European popula-
tions. In gnomAD database, four anonymous male individu-
als from different Northern European populations are shown 
to carry the very late onset mutated allele c.19C>A (p.P7T), 
suggesting yet another possible founder mutation. This is a 
further indication of this new disease being more prevalent 
but apparently unidentified, in part because of the frequently 
‘sporadic’ nature of the late onset X-linked disorders. Sev-
eral different variants identified in different countries also 
suggest existence of yet unknown mutations and therefore 
screening of the small SMPX gene is needed in males with 
unsolved MFM-like pathology.
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Fig. 5  SMPX aggregation in patient muscle. a Congo red staining in 
fluorescence microscopy using Texas red filter showing abundant posi-
tive sarcoplasmic inclusions in muscle biopsy from patient F9 II.1 (scale 
bar = 50 µm). b Confocal sections of a muscle biopsy from patient F8 
III.1. Immunostaining of SMPX or myotilin (green) combined with 
Amytracker 680 (AT680, magenta) shows Amytracker fluorescence 
in SMPX inclusions. A serial section of the same fiber shows no sig-
nal when Amytracker is omitted (BAG3/ctrl), showing that the protein 
inclusions are not autofluorescent. c–e EM findings of patient F9 II.1. 
c One large subsarcolemmal protein inclusion with accumulation of 
filamentous amyloid-like material (black arrowhead). d Myeloid bodies 
(white arrowhead) surrounding sarcoplasmic inclusions (black arrow-
head). e Two classic cytoplasmic bodies (CB) with radiating filaments, 
together with six individual sarcoplasmic inclusions (black arrowheads) 
and nucleus (N)
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Fig. 6  Aggregation propensity of mutant SMPX a In Pasta2.0 predic-
tion, an N-terminal region of wild-type SMPX showed aggregation 
propensity, which was further enhanced by the p.P7T and p.A13V 
mutations, as indicated by the decrease in free energy. The gray 
dashed line shows the aggregation threshold of 5 PASTA units. b 
Representative fractionation experiment demonstrating reduced solu-
bility of mutant SMPX-V5. Total protein staining of the V5 blot, and 
tubulin and histone 3 (H3) stainings of a separate blot are shown as 
loading and fractionation controls. UT, untransfected; N100 and N50, 
normalization samples. (c) Quantification of SMPX-V5 in superna-
tant and pellet fractions. The graph shows mean ± SD from three trip-
licate experiments (n = 9), normalized to total protein loading and to 
the mean of wild-type SMPX within each experiment. Asterisks indi-
cate significant differences compared to WT (two-tailed Mann–Whit-
ney U test with Bonferroni correction; * p < 0.05; ** p < 0.01)
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Fig. 7  Stress granules. a HeLa cells showed cytoplasmic SMPX-V5 
foci that were positive for TIAL1. Scale bar = 20  µm. For other SG 
components in non-treated and MG132-treated cells, see Supple-
mentary Fig. 2 (online resource). b, c Quantification of TIAL1 SGs 
in cells positive for SMPX-V5 (gray bars) and V5-negative cells in 
the same wells (white bars) after MG132 (b) or arsenite (c) stress. 
NT, non-treated; MG, 20  µM MG132 2  h; ARS, 500  µM sodium 
arsenite 45 min; R1/R3, recovery of 1 h / 3 h after stress. The graphs 
show mean ± SD of group means from 4 experiments. Asterisks indi-
cates a significant difference to WT according to Dunnett’s multiple 
comparisons test (p = 0.0038; mean diff. –0.1737; 95% CI –0.2424 
to –0.1050). For details, see Supplementary Tables  2–3 (online 
resource). d Delayed recovery of SMPX-enriched SGs. SGs from the 
V5-positive cells in (b) were classified as V5-enriched (dark bars) or 
non-enriched (light bars) and expressed as SG number per cell. For 
details, see Supplementary Fig. 2 and Supplementary Table 4 (online 
resource)
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